Shots:
- Exact Sciences has introduced the Cancerguard test for early multi-cancer detection & has partnered with Quest Diagnostics to expand patient access in the US
- Cancerguard is supported by extensive clinical data, incl. DETECT-A & ASCEND 2 studies in over 20,000 subjects. Additionally, Exact is enrolling ~25,000 participants in the Falcon registry study following the US FDA’s IDE approval
- Cancerguard test can detect over 50 cancer types & subtypes, demonstrating 68% sensitivity across 6 major cancers & 64% overall sensitivity (excl. breast & prostate) in development studies, with 97.4% specificity to reduce false positives & unnecessary procedures
Ref: Exact Sciences | Image: Exact Sciences | Press Release
Related News:- Pulse Biosciences Receives FDA IDE Approval for nsPFA Cardiac Surgery System to Treat Atrial Fibrillation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
